A Prospective, Randomized, Open-Label Comparison of a Long Acting Basal Insulin Analog LY2963016 to Lantus in Combination with Mealtime Insulin Lispro in Adult Patients with Type 1 Diabetes Mellitus.

Trial Profile

A Prospective, Randomized, Open-Label Comparison of a Long Acting Basal Insulin Analog LY2963016 to Lantus in Combination with Mealtime Insulin Lispro in Adult Patients with Type 1 Diabetes Mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ELEMENT-1
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Jun 2017 Results of clinical outcomes in patients with patients with upper-quartile insulin antibody response data from two studies (ELEMENT-1 and ELEMENT-2) published in the Diabetes Therapy
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top